Bioo Therapeutics has been launched to develop therapeutic agents to combat cancer and other diseases.
Bioo's drug delivery is an antibody conjugation technology that delivers small RNA drugs into specifically targeted cells or tissues.
Scientists at Bioo Scientific have improved the loading capacity of antibody drug carriers and demonstrated their ability to deliver small RNAs into tumours generated from cells expressing the cell-surface target.
Drugs or toxins can be attached to monoclonal antibodies that target a specific cell type forming monoclonal antibody conjugates.
These monoclonal antibody conjugates are used as homing devices to deliver these substances directly into targeted cells.
This technology could revolutionise the delivery of siRNA and other RNAi agents as well as other, more traditional drugs.
The research is being supported by funding in part through grants from the National Science Foundation (NSF), the National Institute of Allergy and Infectious Disease (NIAID) and clients.
